Cambridge Healthtech Institute’s 5th Annual

Small Molecules for Cancer Targets

Part 1: Discovering Tomorrow’s Orally Bio-Available Oncology Therapeutics

September 26-27, 2023

Small molecule-based therapeutic options against traditionally hard-to-drug intracellular oncology targets (like KRAS) are being discovered at a more rapid pace and a few have even reached the market in the past few years. Not only do small molecules offer the promise of medicine in pill form and more affordability than do biologics, but they also expand the types of cancers that can be treated due to their ability to better penetrate the tumor microenvironment (TME) and their ability to penetrate the cell and reach intracellular targets.

Cambridge Healthtech Institute's 5th Annual back-to-back Small Molecules for Cancer Targets conferences showcase the small molecule compounds making progress in oncology. Our expanded coverage via Part 1 and Part 2 reflects the increased number of cellular and immunological oncology mechanisms and targets being uncovered and new discovery chemistry and biology advances enabling progress in modulating them.

Who should attend: Academic, Biotech and Pharma Industry Cancer Drug Discovery Scientists, Directors of Research, Vice Presidents, CSOs in departments such as: Discovery Oncology, Immuno-Oncology, Oncology Discovery Chemistry, Immunology Discovery, Immunology Chemistry.

Coverage will include, but is not limited to:

Kinase-targeted(e.g. HPK1, RIPK1) and Transcription Factor drug leads (TEAD, IKZF and more)
Membrane proteins IO targets: GPCRs, Transporters, especially Solute Carriers
Targeting the MAPK/Ras pathway
Cellular metabolism targets (adenosine and kyneurin pathway)
Targeted-protein degradation (TPD) and other new approaches (synthetic lethality)
Innate immune targets and pattern recog receptors (STING, ROR, TLRs, NLRP3, inflammasome)
Targeting the TME (fibrosis targets, extra-cellular matrix components)
Macrophage checkpoint inhibitors

The deadline for priority consideration is March 17, 2023.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: